Chiesi-Fluidda - Lessons learned from COVID-19 crisis

During the last months a new virus, SARS-CoV-2, spread around the world causing a new pandemic disease, COVID-19 with strange yet unknown characteristics when examining the lungs of patients with imaging techniques. During this webinar not only the results of recent research on COVID with FRI-technology are explained, but also the implications for future treatment of other lung diseases, such as IPF and COPD. PROGRAM The new Pulmonary Vascular Density FRI-Biomarker: An important parameter in determining V/Q mismatch in lung diseases. Dr Jan De Backer, CEO Fluidda Managing the non-intubated COVID-19 with CT outcome parameters Dr. Muriel Lins, Pulmonologist St Maarten, Mechelen, Belgium FRI in Covid-19 and IPF. Investigations of different diseases with the same technology Dr. Muhunthan Thillai, Pulmonologist Papworth Hospital, Cambridge University,UK Ventilation/Perfusion mismatch in COVID-19 Dr. Bruno Hochhegger, Radiotherapist Pontifícia Universidade Católica do Rio Grande do Sul, Brazil Q & A

Topics

• Conclusion

• FRI in Covid-19 and IPF. Investigations of different diseases with the same technology.

• Managing the non-intubated COVID-19 with CT outcome parameters.

• Q&A

• The new Pulmonary Vascular Density FRI-Biomarker: An important parameter in determining V/Q mismatch in lung diseases.

• Ventilation/Perfusion mismatch in COVID-19.

• Welcome